New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.

Manero, MD, discusses findings from the phase 3 COMMANDS trial evaluating luspatercept in patients with myelodysplastic ...

Few patients with MDS receive treatment with hypomethylating agents, with evidence of age-, sex-, and race-related disparities.